CY1117474T1 - Therapeutic regimen of multiple sclerosis (MS) with CAMPATH-1H - Google Patents
Therapeutic regimen of multiple sclerosis (MS) with CAMPATH-1HInfo
- Publication number
- CY1117474T1 CY1117474T1 CY20161100166T CY161100166T CY1117474T1 CY 1117474 T1 CY1117474 T1 CY 1117474T1 CY 20161100166 T CY20161100166 T CY 20161100166T CY 161100166 T CY161100166 T CY 161100166T CY 1117474 T1 CY1117474 T1 CY 1117474T1
- Authority
- CY
- Cyprus
- Prior art keywords
- campath
- treatment
- cycle
- multiple sclerosis
- alemtuzumab
- Prior art date
Links
Abstract
Περιγράφεται μία μέθοδος για την θεραπευτική αγωγή της σκλήρυνσης κατά πλάκας (ΣΚΠ, MS) με το Campath-1Η με σημαντική αποτελεσματικότητα και θετική εικόνα ως προς την ασφάλεια, η οποία προσφέρει μια αποδεκτή αναλογία οφέλους/κινδύνου. Περιγράφεται ειδικά η χρήση του Campath-1Η (αλεμτουζουμάμπη) για την παραγωγή ενός φαρμάκου για την θεραπευτική αγωγή της σκλήρυνσης κατά πλάκας (ΣΚΠ), που περιλαμβάνει έναν πρώτο κύκλο ακολουθούμενο από τουλάχιστον ένα περαιτέρω κύκλο θεραπευτικής αγωγής με Campath-1Η (αλεμτουζουμάμπη), στην οποία κάθε κύκλος θεραπευτικής αγωγής περιλαμβάνει 1-5 ημερήσιες δόσεις, οι οποίες εφαρμόζονται σε διαδοχικές ημέρες, όπου η ημερήσια δόση είναι >0 και ≤ 12 mg, και όπου κάθε κύκλος θεραπευτικής αγωγής απέχει χρονικά από τον επόμενο κύκλο τουλάχιστον 1-24 μήνες. Περιγράφονται επίσης δοσολογικά σχήματα θεραπευτικής αγωγής που περιλαμβάνουν την χορήγηση λιγότερο από 12 mg/ημέρα του Campath-1H για μία περίοδο 1 -5 συνεχόμενων ημερών.A method is described for the treatment of multiple sclerosis (MS, MS) with Campath-1H with significant efficacy and safety-positive image, which offers an acceptable benefit / risk ratio. Specifically described is the use of Campath-1H (alemtuzumab) for the manufacture of a medicament for the treatment of multiple sclerosis (MS), comprising a first cycle followed by at least one further cycle of treatment with Campath-1H (alemtuzumab), in which each treatment cycle comprises 1-5 daily doses, which are applied in successive days, where the daily dose is> 0 and ≤ 12 mg, and where each treatment cycle is at least 1-24 months apart from the next cycle. Therapeutic dosage regimens including administration of less than 12 mg / day of Campath-1H for a period of 1-5 consecutive days are also described.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US84425106A | 2006-09-13 | 2006-09-13 | |
| EP06090169 | 2006-09-14 | ||
| EP07802348.8A EP2066352B1 (en) | 2006-09-13 | 2007-09-11 | Treatment of multiple sclerosis (ms) with campath-1h |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1117474T1 true CY1117474T1 (en) | 2016-10-05 |
Family
ID=58448812
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20161100166T CY1117474T1 (en) | 2006-09-13 | 2016-03-01 | Therapeutic regimen of multiple sclerosis (MS) with CAMPATH-1H |
Country Status (1)
| Country | Link |
|---|---|
| CY (1) | CY1117474T1 (en) |
-
2016
- 2016-03-01 CY CY20161100166T patent/CY1117474T1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1116727T1 (en) | Multiple Sclerosis Treatment With LAQUINIMOD | |
| ECSP055726A (en) | STABILIZED PHARMACEUTICAL COMPOSITION CONTAINING BASIC EXCIPIENTS | |
| CY1116041T1 (en) | INSTRUMENTS AND METHODS FOR THE TREATMENT OF NEURAL DISEASES | |
| DE1001772T1 (en) | IMPROVED ADMINISTRATION TECHNOLOGY FOR MULTIPLE ADMINISTRATION | |
| CY1118543T1 (en) | METHODS OF TREATMENT USING AMMONIA TREATMENT DRUGS | |
| CY1111153T1 (en) | FORM OF OSMOTIC DOSAGE OF PERSONAL LIFE | |
| AR048431A1 (en) | GALENIC FORMULATIONS OF ORGANIC COMPOUNDS | |
| CY1115862T1 (en) | PIRPHENIDONE TREATMENT FOR PATIENTS WITH ABSOLUTE US ADOPTION | |
| RU2010133489A (en) | USE OF GAMMA SECRETASE INHIBITORS FOR TREATMENT OF CANCER | |
| CY1106283T1 (en) | QUINOLINYL-PYRROLOPYRAZOLES | |
| NO20072931L (en) | Improved dosing regimen of temozolomide for the treatment of cancer based on the patient's MGMT level | |
| CO2020008825A2 (en) | Superior g1t38 dosage regimens | |
| CL2007002875A1 (en) | Pharmaceutical composition covered by a film comprising capecitabine and at least one disintegrant, useful in the treatment of cancer for patients who have difficulty swallowing oral solid dosage forms. | |
| MXPA05013974A (en) | Pharmaceutical formulations of amyloid inhibiting compounds. | |
| ES2563068T3 (en) | Multiple sclerosis (MS) treatment with Campath-1H | |
| CY1117474T1 (en) | Therapeutic regimen of multiple sclerosis (MS) with CAMPATH-1H | |
| NO20070763L (en) | Combination therapy with radiolabelled anti-CD20 antibody in the treatment of B-cell lymphoma | |
| AR053154A1 (en) | METHOD OF TREATMENT AND COMBINATION OF ROFLUMILAST AND AN INTEGRINE INHIBITOR | |
| RU2003102451A (en) | METHOD FOR TREATING SYPHYLITIC VASCULITIS | |
| UA115803U (en) | METHOD OF TREATMENT OF VERTEBROGENIC RADICULOPATHIES | |
| UA144735U (en) | METHOD OF TREATMENT OF DIGESTIVE DISEASES | |
| UA58068U (en) | Method for medicamentous treatment of syndrome of polycystic ovary | |
| CY1114286T1 (en) | GLATIRAMER ACETATE AND RASAGILINE Combination Therapy For Multiple Sclerosis | |
| UA3175U (en) | METHOD OF TREATMENT OF MULTIPLE SCLEROSIS | |
| TH101417A (en) | Treatment of multiple sclerosis (MS) |